Novel mAb contraceptive + TDF IVR

Status:Ongoing
Phase:Pre-clinical
Principal Investigator(s):BAUM, MARC MICHAEL
Objective:Formulation of a novel, nonhormonal contraceptive agent based on a multivalent monoclonal antibody (mAb) that blocks sperm from swimming through mucus and accessing the egg with antiretroviral (ARV) agents with demonstrated clinical efficacy in preventing HIV in a behavior-monitoring IVR.
Prevention Option(s):Microbicides
Study Design:
Arms and Assigned Interventions
Description
Mode of DeliveryRing
ARMs
Official Code: Novel mAb contraceptive + TDF IVR
Related Publications:
1R01HD101344-01
Trial Sponsors: NICHD
Start Date
End Date
May 2, 2020
February 21, 2021
Enrollment:0
Age range: ↔ any
Population: